The purpose of this study is to help understand if by adding Niaspan FCT (study drug) to antipsychotic medications will it help maintain or improve cognitve functioning.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
22
NS Early Psychosis Program
Halifax, Nova Scotia, Canada
standardized and experimental measures of attention, memory, and executive function. Measurement tools=MATRICS; DalCAB
Outcomes will be measured by comparison of pre-treatment, post-treatment and twelve month
Time frame: change in cognitive function from baseline to 3, 6, and 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.